Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis pill tested for Long-Term safety in thousands of patients

NCT ID NCT06550076

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is checking the long-term safety and side effects of an experimental pill called TAK-279 in about 2,100 adults with moderate-to-severe plaque psoriasis. All participants will take the drug for up to 4 years, with regular clinic visits. The goal is to see how well people tolerate the treatment over time, not to cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

2,099 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: Part A: * Participant is willing and able to understand and fully comply with study procedures and requirements (including digital tools and applications), in the opinion of the investigator. * Participant has provided written informed consent and any required privacy authorization before the initiation of any study procedures. * Participant is aged 18 years or older at the time of consent. * Participant has a diagnosis of chronic plaque psoriasis for \>=6 months prior to the screening visit. * Participant has stable plaque psoriasis defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis for \>=6 months before screening. * Participant has moderate-to-severe plaque psoriasis as defined by a PASI score \>=12 and a sPGA score \>=3 at screening and Day 1. * Participant has plaque psoriasis covering \>=10% of his or her total BSA at screening and Day 1. * Participant must be a candidate for phototherapy or systemic therapy. Part B: \- Participant has completed 52 weeks of treatment (TAK-279-3001 or Part A) or 60 weeks of treatment (TAK-279-3002), or 16 weeks of treatment (TAK-279-PsO-3004) in their parent study. Main Exclusion Criteria Part A: * Participant has evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary. * Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs, during the trial period for an immune-related disease (e.g., inflammatory bowel disease). * Participant has any clinically significant medical condition, evidence of an unstable clinical condition (e.g., cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or immunologic), or vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results. These include but are not limited to: 1. Participant has a history of known or suspected condition/illness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency; splenectomy. 2. Participant had a major surgery within 60 days prior to Day 1 or has a major surgery planned during the study. 3. Participant has unstable, poorly controlled, or severe hypertension at screening, confirmed by 2 repeat assessments. 4. Participant has a history of Class III or IV congestive heart failure as defined by New York Heart Association criteria. 5. Participant has a history of cancer or lymphoproliferative disease, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix. 6. For participants with asthma, chronic obstructive pulmonary disease, or other pulmonary illnesses, participant has been hospitalized in the past 3 months, has ever required intubation for treatment, currently requires oral corticosteroids, or has required more than 1 course of oral corticosteroids within 6 months prior to Day 1. 7. Participant has any of the following cardiovascular disease history: A new diagnosis of atrial fibrillation or an episode of atrial fibrillation with rapid ventricular response or other dysrhythmia, non-acute cardiac hospitalization (e.g., pacemaker implantation), pulmonary embolism, or deep venous thrombosis within the past 6 months prior to screening. Any history of cerebrovascular event, myocardial infarction, coronary stenting, or aortocoronary bypass surgery. If, however, the investigator determines there are no suitable treatment alternatives available for the participant and it has been at least 6 months since the occurrence of any such event, the participant may enroll. 8. Participant has ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if he or she participated in the study, in the opinion of the investigator. 9. Participant has significant/uncontrolled psychiatric illness, in the opinion of the investigator. 10. Participant has any lifetime history of suicidal ideation, suicidal behavior, or suicidal attempts by 1) medical history; or 2) by Columbia-Suicide Severity Rating Scale (C-SSRS) documentation at screening or by answering "yes" to Question 5 for suicidal ideation on the C-SSRS at screening; or 3) is clinically deemed to have a suicide risk by the investigator. 11. Participant has a patient health questionnaire - 8 (PHQ-8) score of 15 or above at screening. 12. Participant has a history of clinically significant drug or alcohol abuse within 12 months prior to Day 1. * Participant has received any of the following biologics or biosimilar versions within the time frame indicated or 5 half-lives, whichever is longer: 1. Antibodies to interleukin (IL) -12/-23, IL-17, or IL-23 (eg, ustekinumab, secukinumab, tildrakizumab, ixekizumab, or guselkumab) within 6 months prior to Day 1. 2. Tumor necrosis factor inhibitor(s) (e.g., etanercept, adalimumab, infliximab, certolizumab) within 2 months prior to Day 1. 3. Agents that modulate integrin pathways to impact lymphocyte trafficking (e.g., natalizumab) or agents that modulate B cells or T cells (e.g., alemtuzumab, abatacept, or visilizumab) within 3 months prior to Day 1. 4. Rituximab or other immune cell-depleting therapy within 6 months prior to Day 1. * Participant has any previous exposure to TAK-279 (also known as NDI-034858) or other TYK2 inhibitors, including deucravacitinib, or participant participated in any study that included a TYK2 inhibitor (e.g., deucravacitinib, VTX958, GLPG3667, etc.), unless the participant has documentation of post-trial unblinding that confirms the partcipant did not receive a TYK2 inhibitor. * Participant has a known or suspected allergy to TAK-279 or any of its components. Part B: * Participant has completed the parent study or Part A but was permanently discontinued from treatment. * Participant had evidence of significant noncompliance with study visits or study drug in the parent study or Part A, as defined in the parent study protocol or in the opinion of the investigator. * Participant has met criteria for termination from the parent study or Part A, regardless of whether or not the participant was terminated from the parent study or Part A. * Participant has developed evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis) since enrollment in the parent study or Part A. * Participant has developed a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments. * Participant has received a prohibited psoriasis treatment during the parent study or Part A, whether or not that treatment was documented as a concomitant medication and is expected to continue that treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • 4 Medical Clinical Solutions - Swinton - PPDS

    Ilford, Essex, IG1 4HP, United Kingdom

  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdansku

    Gdansk, Pomeranian Voivodeship, 80-382, Poland

  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Katowicach

    Katowice, Silesian Voivodeship, 40-040, Poland

  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu

    Poznan, Greater Poland Voivodeship, 60-702, Poland

  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie

    Warsaw, Masovian Voivodeship, 02-672, Poland

  • ALLCUTIS Research, LLC.

    Portsmouth, New Hampshire, 03801, United States

  • Accellacare of Cary

    Cary, North Carolina, 27518, United States

  • Accellacare of Northamptonshire

    Harrow, Middlesex, HA1 3UJ, United Kingdom

  • Advanced Clinical Research Institute (ACRI) - Florida

    Tampa, Florida, 33607-6429, United States

  • Advanced Medical Research, PC

    Sandy Springs, Georgia, 30328, United States

  • Aesthetic dermatology clinic of prof. J. Kisis

    Riga, LV-1003, Latvia

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 212001, China

  • Alberta DermaSurgery Centre - Probity

    Edmonton, Alberta, T6G 1C2, Canada

  • Alfred Health

    Parkville, Victoria, 3050, Australia

  • Allergo-Derm Bakos Kft.

    Szolnok, Jász-Nagykun-Szolnok, 5000, Hungary

  • Alliance Clinical Trials

    Waterloo, Ontario, N2J 1C4, Canada

  • Ambulatorium Sp. z o.o.

    Elblag, 82-300, Poland

  • Apex Clinical Research Center

    Mayfield Heights, Ohio, 44124-4005, United States

  • Arlington Dermatology

    Rolling Meadows, Illinois, 60008-3811, United States

  • Arlington Research Center

    Arlington, Texas, 76011-3800, United States

  • Azienda Usl Toscana Centro - Firenze

    Florence, Tuscany, 50125, Italy

  • Beacon Dermatology - Probity

    Calgary, Alberta, T3A 2N1, Canada

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100050, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100730, China

  • Bellaire Dermatology Associates

    Bellaire, Texas, 77401-3505, United States

  • Bexley Dermatology Research - Probity - PPDS

    Bexley, Ohio, 43209, United States

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas, 71913-6475, United States

  • CCA Medical Research - Probity

    Ajax, Ontario, L1S 7K8, Canada

  • CCR Ostrava s.r.o.

    Ostrava, Moravian-Silesian Region, 702 00, Czechia

  • CLINTRIAL s.r.o.

    Prague, 100 00, Czechia

  • Cahaba Dermatology Skin Health Center

    Hoover, Alabama, 35244-2111, United States

  • Canadian Dermatology Centre - Probity

    Toronto, Ontario, M3B 0A7, Canada

  • Care Clinic

    Red Deer, Alberta, T4P 1K4, Canada

  • Center For Clinical Studies, LTD. LLP - 451 N Texas Ave

    Webster, Texas, 77598-4927, United States

  • Center for Dermatology Clinical Research

    Fremont, California, 94538, United States

  • Centre Hospitalier Le Mans

    Le Mans, Sarthe, 72037, France

  • Centre Hospitalier Universitaire de Saint Etienne

    Saint-Etienne, 42270, France

  • Centro de Investigacion Clinica

    Ciudad Autónomade Buenos Aires, C1060ABN, Argentina

  • Centro de Investigaciones Médicas Tucumán

    San Miguel de Tucumán, Tucumán Province, T4000, Argentina

  • Centrum Badan Klinicznych Pi-house Sp. Z O. O.

    Gdansk, Pomeranian Voivodeship, 80-546, Poland

  • Centrum Medyczne ALL-MED

    Krakow, Lesser Poland Voivodeship, 30-033, Poland

  • Centrum Medyczne Angelius Provita

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Centrum Medyczne Bydgoszcz- PRATIA

    Bydgoszcz, 85-796, Poland

  • Centrum Medyczne Katowice - PRATIA

    Katowice, Lower Silesian Voivodeship, 40-081, Poland

  • Centrum Terapii Współczesnej J.M. Jasnorzewska S.K.A.

    Lódz, Lódzkie, 90-338, Poland

  • Centrum Uslug Medycznych MaxMed

    Bochnia, 32-700, Poland

  • Chaim Sheba Medical Center

    Ramat Gan, 5265602, Israel

  • Chosun University Hospital

    Gwangju, Gwangju Gwang'yeogsi, 61453, South Korea

  • Chung-Ang University Hospital

    Seoul, South Korea

  • Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p

    Wroclaw, Lower Silesian Voivodeship, 50-566, Poland

  • ClinicMed Daniluk, Nowak Spolka Komandytowa

    Bialystok, Podlaskie Voivodeship, 15-879, Poland

  • Clinical Best Solutions Sp. z o.o. S.K.

    Lublin, Lublin Voivodeship, 20-011, Poland

  • Clinical Best Solutions Sp. z o.o. S.K.

    Warsaw, Masovian Voivodeship, 00-710, Poland

  • Clinical Research Group Sp. z o.o

    Warsaw, Masovian Voivodeship, 01-142, Poland

  • Conexa Investigación Clínica S.A.

    Buenos Aires, Ciudad Autónoma de BuenosAires, C1012, Argentina

  • Copernicus Podmiot Leczniczy Sp. z o.o, Szpital Sw. Wojciecha, Oddzial Dermatologii

    Gdansk, Pomeranian Voivodeship, 80-462, Poland

  • Cumberland Skin Center for Clinical Research - Objective Health - PPDS

    Hermitage, Tennessee, 37076-3497, United States

  • DS Research - 1005 E. Lewis & Clark Pkwy Indiana Location

    Clarksville, Indiana, 47129-2201, United States

  • Dartmouth Hitchcock Medical Center - Old Etna Rd

    Lebanon, New Hampshire, 03766-1937, United States

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana, 46250, United States

  • Debreceni Egyetem

    Debrecen, 4032, Hungary

  • Derm-art

    Gdynia, Pomeranian Voivodeship, 81-415, Poland

  • DermEdge Research - Probity

    Mississauga, Ontario, L5H 1G9, Canada

  • DermEffects

    London, Ontario, N6H 5L5, Canada

  • Dermamedica, s.r.o. - Kozni Ambulance Nachod

    Náchod, Hradec Králové Region, 547 01, Czechia

  • Dermatologikum Hamburg

    Hamburg, 20354, Germany

  • Dermatology Clinical Research Center of San Antonio

    San Antonio, Texas, 78229-3409, United States

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, 510091, China

  • Dermatology Institute and Skin Care Center

    Santa Monica, California, 90404-2216, United States

  • Dermatology Research Institute, Inc.

    Calgary, Alberta, T3A 2N1, Canada

  • Dermatology Specialists Research - 3810 Springhurst Blvd

    Louisville, Kentucky, 40241-6162, United States

  • Dermatology and Ophthalmology Kume Clinic

    Sakaishi, Ôsaka, 593-8324, Japan

  • Dermatrials Research

    Hamilton, Ontario, L8N 1Y2, Canada

  • Dermedic Jacek Zdybski

    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, 27-400, Poland

  • Dermoklinika-Centrum Medyczne s.c

    Lodz, Łódź Voivodeship, 90-436, Poland

  • Dermskin s.r.o

    Olomouc, Olomouc Region, 779 00, Czechia

  • Diagnostic Consultative Center Sveti

    Haskovo, 6300, Bulgaria

  • Diagnostic Consultative Center XXVIII - Sofia - EOOD

    Sofia, Sofia-Grad, 1592, Bulgaria

  • Diagnostic Consultative Centre - Focus-5 - LZIP EOOD

    Sofia, Sofia-Grad, 1463, Bulgaria

  • Diagnostic and Consulting Center Aleksandrovska EOOD

    Sofia, Sofia-Grad, 1431, Bulgaria

  • Diamond Clinic Sp. z o.o., Diamond Medical Center

    Krakow, 31-559, Poland

  • Direct Helpers Medical Center

    Hialeah, Florida, 33012, United States

  • Divine Dermatology and Aesthetics, LLC

    Atlanta, Georgia, 30315-2042, United States

  • Dr. S. K. Siddha Medicine Professional Corporation | Newmarket, Canada

    Newmarket, Ontario, Canada

  • Driven Research LLC

    Coral Gables, Florida, 33134-3901, United States

  • ETG Siedlce - PPDS

    Siedlce, Masovian Voivodeship, 08-110, Poland

  • ETG Warszawa - PPDS

    Warsaw, Masovian Voivodeship, 02-677, Poland

  • ETYKA Osrodek Badan Klinicznych

    Olsztyn, 10-117, Poland

  • Enverus Medical Research - Probity

    Surrey, British Columbia, V3V 0C6, Canada

  • FXM Clinical Research Ft. Lauderdale, LLC

    Fort Lauderdale, Florida, 33308-5211, United States

  • FXM Clinical Research Miami, LLC

    Miami, Florida, 33175-3582, United States

  • FXM Research Miramar

    Miramar, Florida, 33027-4714, United States

  • Fachklinik Bad Bentheim

    Bad Bentheim, Lower Saxony, 48455, Germany

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, 779 00, Czechia

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, 030001, China

  • First OC Dermatology Research Inc.

    Fountain Valley, California, 92708, United States

  • Florida Academic Centers Research

    Miami, Florida, 33136-1003, United States

  • Fukuoka University Hospital

    Fukuoka, Hukuoka, 814-0180, Japan

  • FutureMeds - Targowek - PPDS

    Warsaw, Masovian Voivodeship, 03-291, Poland

  • GCM Medical Group

    San Juan, 00909-3004, Puerto Rico

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia Hui, 750004, China

  • Georgia Skin and Cancer Clinic

    Savannah, Georgia, 31419-1768, United States

  • Globe Badania Kliniczne Spolka z o.o. - Klodzko

    Kłodzko, Lower Silesian Voivodeship, 57-300, Poland

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510080, China

  • Guelph Dermatology Research - Probity

    Guelph, Ontario, N1L 0B7, Canada

  • Hautarztpraxis Mahlow

    Blankenfelde-Mahlow, Brandenburg, 15831, Germany

  • Health Center 4-1 Grebenscikova Str

    Riga, LV-1003, Latvia

  • Health Center 4-Skanstes iela 50

    Riga, LV-1013, Latvia

  • Henderson Clinical Trials

    Henderson, Nevada, 89052, United States

  • High-Med Przychodnia Specjalistyczna

    Warsaw, Masovian Voivodeship, 01-817, Poland

  • Hino Dermatology Clinic

    Fukutsu-shi, Fukuoka, 811-3217, Japan

  • Hopital Charles Nicolle-1 Rue de Germont

    Rouen, 76031fr, France

  • Hospital Clinico San Carlos

    Donostia / San Sebastian, Guipúzcoa, 20004, Spain

  • Hospital de Manises

    Manises, Valencia, 46940, Spain

  • Houston Center for Clinical Research, LLC

    Sugar Land, Texas, 77479-1001, United States

  • Huashan Hospital Fudan University - PPDS

    Shanghai, Minhang District, 201100, China

  • IRCCS Istituto Clinico Humanitas

    Rozzano, Milano, 20089, Italy

  • International Clinical Research US LLC

    Murfreesboro, Tennessee, 37130-2450, United States

  • JCHO Tokyo Yamate Medical Center

    Shinjuku-ku, Tokyo-To, 169-0073, Japan

  • JR Sapporo Hospital

    Sapporo, Hokkaidô, 060-0033, Japan

  • Jichi Medical University Hospital

    Shimotsuke-shi, Tochigi, 329-0498, Japan

  • Johnson Dermatology Clinic

    Fort Smith, Arkansas, 72916-6103, United States

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, 81362, Taiwan

  • Karma Clinical Trials

    St. John's, Newfoundland and Labrador, A1A 4Y3, Canada

  • Kingsway Clinical Research - Probity

    Etobicoke, Ontario, M8X 1Y9, Canada

  • Klinika Ambroziak Dermatologia

    Warsaw, Masovian Voivodeship, 02-953, Poland

  • Klinika Reuma Park sp . zoo Sp.k.

    Warsaw, Masovian Voivodeship, 02-691, Poland

  • Klinikum Oldenburg

    Oldenburg, Lower Saxony, 26133, Germany

  • Klinische Forschung Dresden Gmbh

    Dresden, Saxony, 01069, Germany

  • Konkuk University Medical Center

    Gwangjin-Gu, Seoul Teugbyeolsi, 05030, South Korea

  • Krakowskie Centrum Medyczne Sp. z o.o.

    Krakow, Lesser Poland Voivodeship, 31-501, Poland

  • Kyung Hee University Hospital

    Seoul, 2447, South Korea

  • Lawrence J Green, MD LLC

    Rockville, Maryland, 20850, United States

  • Leavitt Clinical Research

    Idaho Falls, Idaho, 83404-8322, United States

  • Lenus Research & Medical Group

    Sweetwater, Florida, 33172, United States

  • Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity

    Hamilton, Ontario, L8L 3C3, Canada

  • Long Beach Research Institute

    Long Beach, California, 90805, United States

  • Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska

    Lublin, Lublin Voivodeship, 20-573, Poland

  • Lynderm Research Inc - Probity

    Markham, Ontario, L3P 1X3, Canada

  • MC Comac Medical

    Sofia, Sofia-Grad, 1612, Bulgaria

  • MICS Centrum Medyczne Torun

    Torun, 87-100, Poland

  • MICS Centrum Medyczne Warszawa

    Warsaw, Masovian Voivodeship, 00-874, Poland

  • Mackay Memorial Hospital-Taipei branch

    Taipei, Taiwan

  • Marietta Dermatology & The Skin Cancer Center - Marietta

    Marietta, Georgia, 30060-7902, United States

  • Markusovszky Egyetemi Oktatókórház

    Szombathely, Vas County, Hungary

  • Medical Center Asklepii OOD

    Dupnitsa, Kyustendil, 2600, Bulgaria

  • Medical Center Hera EOOD-Sofia

    Sofia, Sofia-Grad, 1510, Bulgaria

  • Medical Center Medconsult Pleven OOD

    Pleven, Bulgaria

  • Medical Center Unimed EOOD-Sevlievo

    Sevlievo, Gabrovo, 5400, Bulgaria

  • Medical Corporation Jitai-kai Tachikawa Dermatology Clinic

    Tachikawa-shi, Tokyo, 190-0023, Japan

  • Medical Corporation Kojinkai Sapporo Skin Clinic

    Sapporo, Hokkaidô, 060-0063, Japan

  • Medical Dermatology Specialists

    Phoenix, Arizona, 85006, United States

  • Mediprobe Research Inc

    London, Ontario, N5X 2P1, Canada

  • Metropolis Dermatology Downtown LA - Probity - PPDS

    Los Angeles, California, 90017-5310, United States

  • Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia

    Sofia, Sofia-Grad, 1606, Bulgaria

  • Minnesota Clinical Study Center

    New Brighton, Minnesota, 55112, United States

  • Modern Research Associates

    Dallas, Texas, 75231-6077, United States

  • Montefiore AOA - BRANY

    The Bronx, New York, 10467, United States

  • Multiprofile Hospital For Active Treatment Dr Tota Venkova

    Gabrovo, Bulgaria

  • NZOZ Osteo Medic SC Artur Racewicz Jerzy Supronik

    Bialystok, Podlaskie Voivodeship, 15-351, Poland

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, 467-8602, Japan

  • National Cheng Kung University

    Tainan, Tainan City, 70403, Taiwan

  • National Taiwan University Hospital

    Zhong Zheng Qu, 100, Taiwan

  • National Taiwan University Hospital, Hsin-Chu Branch

    Hsinchu, 300, Taiwan

  • Nemocnice AGEL Novy Jicin a.s

    Nový Jičín, Moravian-Silesian Region, Czechia

  • Nippon Life Hospital

    Osaka, Osaka, 550-0006, Japan

  • Noble Clinical Research

    Tucson, Arizona, 85704, United States

  • North Bay Dermatology Center - Probity

    North Bay, Ontario, P1B 3Z7, Canada

  • North Texas Center for Clinical Research

    Frisco, Texas, 75034, United States

  • North York Research Inc. - Probity

    Toronto, Ontario, M2N 3A6, Canada

  • NorthShore Medical Group Dermatology - Skokie

    Skokie, Illinois, 60077-1049, United States

  • Northridge Clinical Trials

    Northridge, California, 91325-4122, United States

  • Oakland Hills Dermatology - 3400 Auburn Rd

    Auburn Hills, Michigan, 48326-3396, United States

  • Office of Mireille Ruer-Mulard, MD

    Martigues, Paca, 13500, France

  • Ohyama Dermatology Clinic

    Kumamoto, 861-4101, Japan

  • Oregon Medical Research Center PC

    Portland, Oregon, 97201, United States

  • Ostrowieckie Centrum Medyczne Anna Olech Cudzik Krzysztof Cudzik s.c.

    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, 27-400, Poland

  • Outpatient Clinic Adoria

    Riga, LV-1011, Latvia

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100044, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

  • Praglandia

    Prague, 150 00, Czechia

  • Pratia Brno s.r.o. - PRATIA - PPDS

    Brno, South Moravian, 602 00, Czechia

  • Pratia MCM Krakow

    Krakow, Lesser Poland Voivodeship, 30-727, Poland

  • Pratia Pardubice a.s. - PRATIA - PPDS

    Pardubice, Pardubice Region, 530 02, Czechia

  • Praxis fur Dermatologie and Venerologie

    Dresden, Saxony, 01097, Germany

  • Presidio Ospedaliero Gaspare Rodolico

    Catania, Sicily, 95123, Italy

  • Pro Familia Altera Sp. z o.o.

    Katowice, Silesian Voivodeship, 40-648, Poland

  • Pro Life Medica Sp. z o.o. ETG Lublin

    Lublin, 20-412, Poland

  • Prof. MUDr. Petr Arenberger, DrSc. - CRC - PPDS

    Prague, 110 00, Czechia

  • Promed P. Lach R. Głowacki Sp. j., Centrum Medyczne Promed

    Krakow, 31-411, Poland

  • Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey, 08520, United States

  • RCMed Oddzial Sochaczew

    Sochaczew, Masovian Voivodeship, 96-500, Poland

  • Rabin Medical Center - PPDS

    Petah Tikva, Israel

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, 430060, China

  • Renstar Medical Research -21 NE 1st Ave

    Ocala, Florida, 34470, United States

  • Revival Research Corporation - ClinEdge

    Troy, Michigan, 48084-3536, United States

  • Revival Research Corporation - Florida - ClinEdge - PPDS

    Doral, Florida, 33122-1902, United States

  • Rheumatology Clinic NZOZ Lecznica MAK-MED

    Nadarzyn, Masovian Voivodeship, 05-830, Poland

  • Riga 1st Hospital

    Riga, LV-1001, Latvia

  • Royalderm Agnieszka Nawrocka

    Warsaw, 02 962, Poland

  • SRH Wald-Klinikum Gera GmbH

    Gera, Thuringia, 07548, Germany

  • Sadick Research Group

    New York, New York, 10075-0385, United States

  • Saguaro Dermatology Associates, LLC - Probity - PPDS

    Phoenix, Arizona, 85008-3884, United States

  • Salford Royal Hospital - PPDS

    Salford, Lancashire, M6 8HD, United Kingdom

  • San Antonio

    San Antonio, Texas, 78213-2250, United States

  • San Marcus Research Clinic Inc

    Miami Lakes, Florida, 33014, United States

  • Seikoukai Omi Medical Center

    Kusatsu-shi, Shiga, 525-8585, Japan

  • Semigallia

    Kuldīga, LV-3301, Latvia

  • Seoul National University Bundang Hospital

    Beon-gil Bundang-gu, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 3080, South Korea

  • Shandong Provincial Hospital

    Jinan, Shandong, 250013, China

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, 200020, China

  • Shirasaki Dermatology Clinic

    Takaoka-shi, Toyama, 933-0871, Japan

  • Siena Medical Research Corporation

    Montreal, Quebec, H3Z 2S6, Canada

  • SimcoDerm Medical and Surgical Dermatology Centre - Probity

    Barrie, Ontario, L4M 7G1, Canada

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310016, China

  • Skin Centre for Dermatology

    Peterborough, Ontario, K9J 5K2, Canada

  • Skin Health Institute Inc - Probity - PPDS

    Carlton, Victoria, 3053, Australia

  • Skin Sciences, PLLC

    Louisville, Kentucky, 40217-1444, United States

  • Skin Specialists PC

    Omaha, Nebraska, 68144, United States

  • Skinsense Medical Research - Probity

    Saskatoon, Saskatchewan, S7K 0H6, Canada

  • Smite Aija medical practice in dermatology, venerology

    Talsi, Talsu Aprinkis, LV-3201, Latvia

  • Somogy Megyei Kaposi Mór Oktató Kórház

    Kaposvár, Somogy County, 7400, Hungary

  • Soon Chun Hyang University Hospital Seoul

    Seoul, Seoul Teugbyeolsi, 04401, South Korea

  • St George Dermatology and Skin Cancer Center - Probity - PPDS

    Kogarah, New South Wales, 2217, Australia

  • St. Luke's International Hospital

    Chuo-ku, Tokyo, 104-8560, Japan

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510120, China

  • TCR Medical Corporation

    San Diego, California, 92123-1523, United States

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • Takagi Dermatological Clinic

    Obihiro-Shi, Hokkaidô, 080-0013, Japan

  • Texas Dermatology and Laser Specialists-San Antonio-7703 Floyd Curl Dr

    San Antonio, Texas, 78218-3128, United States

  • The 1st Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000, China

  • The 2nd Hospital of Xi'An Jiaotong University

    Xi'an, Shan'xi, 710004, China

  • The Catholic University of Korea, Bucheon St. Mary's Hospital

    Bucheon-si, Gyeonggido, 14647, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seocho-Gu, Seoul Teugbyeolsi, 06591, South Korea

  • The Centre For Dermatology

    Richmond Hill, Ontario, L4B 1A5, Canada

  • The Centre for Clinical Trials Inc.

    Oakville, Ontario, L6J 7W5, Canada

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400016, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, 350005, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050031, China

  • The Skin Center - Probity

    Benowa, Queensland, 4217, Australia

  • The Skin Surgery Center for Clinical Research - Objective Health - PPDS

    Winston-Salem, North Carolina, 27103-7109, United States

  • The University of Hong Kong - Shenzhen Hospital

    Shenzhen, China

  • Tokyo Medical University Hospital

    Tokyo, 160-0023, Japan

  • Tokyo Teishin Hospital

    Sumida-Ku, Tokyo, Japan

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, 430030, China

  • Toronto Research Centre

    Toronto, Ontario, M3H 5Y8, Canada

  • Toronto Research Centre - Probity

    Toronto, Ontario, M4W 2N4, Canada

  • Total Dermatology

    Birmingham, Alabama, 35205, United States

  • Twoja Przychodnia - Nowosolskie Centrum Medyczne sp. z o.o

    Nowa Sól, 67-100, Poland

  • Twoja Przychodnia PCM

    Poznan, Greater Poland Voivodeship, 61-293, Poland

  • Twoja Przychodnia Szczecińskie Centrum Medyczne Sp. z o.o.

    Szczecin, West Pomeranian Voivodeship, 71-500, Poland

  • UC Davis Dermatology Clinic

    Sacramento, California, 95816-3370, United States

  • UCLA University of California Los Angeles

    Los Angeles, California, 90024, United States

  • UNISON Clinical Trials (Shahram Jacobs md inc.)

    Sherman Oaks, California, 91403, United States

  • UT Physicians Dermatology - Bellaire Station

    Bellaire, Texas, 77401, United States

  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST)

    Wuhan, Hubei, 430022, China

  • University Clinical Trials

    San Diego, California, 92123, United States

  • University of Alabama Hospital - Whitaker Clinic -

    Birmingham, Alabama, 35233-2110, United States

  • University of Michigan Hospital - 1500 E Medical Center Dr

    Ann Arbor, Michigan, 48109-5360, United States

  • University of Pittsburgh Medical Center-3601 5th Ave

    Pittsburgh, Pennsylvania, 15213-3403, United States

  • Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Lodzi, Klinika Dermatologii i Wenerologii

    Lodz, 90-647, Poland

  • VIDA Dermatology - Probity

    Edmonton, Alberta, T6H 4J8, Canada

  • Velocity Clinical Research - High Wycombe - PPDS

    High Wycombe, Buckinghamshire, HP11 2QW, United Kingdom

  • Velocity Clinical Research North London - Percy Road - PPDS

    London, Middlesex, N12 8BU, United Kingdom

  • Velocity Skierniewice Sp. z o.o.

    Skierniewice, Łódź Voivodeship, 96-100, Poland

  • Veseliba un estetika Ltd.

    Riga, LV-1009, Latvia

  • Virginia Clinical Research - 6160 Kempsville Cir

    Norfolk, Virginia, 23507, United States

  • Western Health - Sunshine Hospital

    Parkville, Victoria, 3050, Australia

  • Whipps Cross University Hospital

    London, London, City of, E11 1NR, United Kingdom

  • Wiseman Dermatology Research Inc.

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Wright State Physicians

    Fairborn, Ohio, 45324, United States

  • XLR8 Medical Research

    Windsor, Ontario, N8T 1E6, Canada

  • Yonsei University Wonju Severance Christian Hospital

    Wŏnju, Gangwon-do, 220-701, South Korea

  • Zenith Research, Inc.

    Beverly Hills, California, 90212, United States

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, 310000, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510280, China

  • dermMEDICA Sp. z o.o. | Krzysztofa Kolumba 6

    Wroclaw, 51-503, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.